| Today's Big NewsNov 14, 2022 |
| By Nick Paul Taylor Roche’s bet on the resurrection of Alzheimer’s disease candidate gantenerumab has flopped. The drug candidate failed to improve the rate of cognitive and functional decline in a pair of phase 3 clinical trials, delivering yet another blow to the field. |
|
|
|
By Max Bayer Roivant is cutting 12% of its staff as part of a larger effort to extend the company's cash runway into 2025. The company's statement did not elaborate on which spinoff companies would be affected. |
By Andrea Park 2022 is undoubtedly a fraught time in the history of the women’s movement, but it is also an inspiring one, as people from every corner of the globe come together in support of the idea that women deserve equal rights. That double-edged sentiment echoes throughout this year’s list of the 20 fiercest women in life sciences. |
Sponsored by Phreesia Life Sciences While the industry has yet to address a big barrier to trial enrollment—low patient knowledge—the good news is that patients want to learn more, according to survey data from Phreesia Life Sciences. |
By Gabrielle Masson The third quarter of 2022 has proved to be the season of biotech pipeline culls, with three more companies setting out plans this morning to shed programs in hopes that the lighter load will allow them to forge ahead in rocky market conditions. |
Sponsored by ThermoFisher Scientific Every mRNA manufacturing process step adds complexity and cost, so it’s important to ensure steps are compatible and integrated with each other. Explore each intertwined step in this infographic. |
By Max Bayer Ionis and gene editing company Metagenomi have signed onto a research pact that could ultimately total eight targets worth up to almost $3 billion. It's a gargantuan deal with a value ceiling that rivals and exceeds similar deals from the world's largest pharmas. |
By James Waldron Lantheus is paying $260 million upfront for a double bill of licenses for two of POINT Biopharma’s radiopharmaceutical oncology candidates, with another $1.8 billion tied up in biobucks. |
By Annalee Armstrong Intellia Therapeutics has a few more drops of evidence that its second gene editing candidate may offer a functional cure for hereditary angioedema, a rare inherited disorder that causes rapid swelling all over the body. |
By Annalee Armstrong Patients are living longer than expected in Sellas Life Sciences’ phase 3 trial for an acute myeloid leukemia drug. That’s great news for patients and has spurred a protocol amendment for the study—but the question remains: Is it because of the biotech’s drug? |
By Nick Paul Taylor New device, new trial, same flop. That is the story at Satsuma Pharmaceuticals, which suffered a second stock-crushing phase 3 bellyflop after tweaks to its migraine nasal drug delivery device failed to yield an asset capable of beating placebo. |
By Helen Floersh A next-generation oncolytic virus carrying a tumor-tackling protein armed with cytokines and cetuximab showed survival benefits in mouse models of glioblastoma multiforme, a type of brain cancer. |
By Fraiser Kansteiner Cancer, COVID-19 and copycat drugs dominated the agenda at last week's meeting of the European Medicines Agency’s human medicines committee, which has endorsed four new pharmaceuticals and pushed for label extensions on 11 others. |
By Healthcare Staff Fierce Healthcare's editorial team brings you the latest news and trends from the HLTH 2022 conference and expo in Las Vegas. |
By Conor Hale The collaboration will start with jointly identified oncology targets and then employ Exscientia’s AI platform to design small-molecule drugs. |
By Kevin Dunleavy The rush is on as biopharma companies from the west are flocking to Asia and, more specifically, to business-friendly Singapore in their hopes of tapping into a massive and growing market. Monday, BioNTech revealed more about its plan to establish a stronghold on the island nation, saying it had acquired a manufacturing facility from Novartis that will also serve as its Asia-Pacific regional headquarters. |
By Jacqueline Renfrow Johnson & Johnson’s R&D unit Janssen is driving awareness among Black Americans of the risks for PAD-related amputations in the “Save Legs. Change Lives” campaign. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we share some highlights from Fierce Biotech's Cell and Gene Therapy Forum in case you missed it. |
|
|---|
|
|
|
Tuesday, December 6, 2022 | 10am ET / 7am PT The development of therapeutic antibodies has been challenged by the difficulty to generate such intricate molecules. Here, we show that ProBio has established proprietary fast CMC platform guaranteeing the delivery of monoclonal antibody with high titer. Register now. 
|
|
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
